BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

SHANGHAI, Feb. 10, 2025 /PRNewswire/ — On December 19, 2024, BioRay Pharmaceutical Co., Ltd. (“BioRay”) announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product,…